Immuno- μSARS2 Chip: A Peptide-based microarray to assess COVID-19 prognosis based on immunological fingerprints

Guercetti, Julian; Alorda, Marc; Sappia, Luciano; Galve, Roger; Duran-Corbera, Macarena; Pulido, Daniel; Berardi, Ginevra; Royo, Miriam; Lacoma, Alicia; Muñoz, José; Padilla, Eduardo; Castañeda, Silvia; Sendra, Elena; Horcajada Gallego, Juan Pablo; Gutierrez-Galvez, Agustín; Marco Sola, Santiago; Salvador, J-Pablo; Marco, M-Pilar

doi:http://dx.doi.org/10.1021/acsptsci.4c00727

Immuno- μSARS2 Chip: A Peptide-based microarray to assess COVID-19 prognosis based on immunological fingerprints

Citation

Guercetti J, Alorda M, Sappia L, Galve R, Duran-Corbera M, Pulido D, et al. Immuno- μSARS2 Chip: A Peptide-based microarray to assess COVID-19 prognosis based on immunological fingerprints. ACS Pharmacol Transl Sci. 2025 Feb 21;8(3):871-84. DOI: 10.1021/acsptsci.4c00727

Abstract

A multiplexed microarray chip (Immuno-μSARS2) aiming at providing information on the prognosis of the COVID-19 has been developed. The diagnostic technology records information related to the profile of the immunological response of patients infected by the SARS-CoV-2 virus. The diagnostic technology delivers information on the avidity of the sera against 28 different peptide epitopes and 7 proteins printed on a 25 mm2 area of a glass slide. The peptide epitopes (12-15 mer) derived from structural proteins (Spike and Nucleocapsid) have been rationally designed, synthesized, and used to develop Immuno-μSARS2 as a multiplexed and high-throughput fluorescent microarray platform. The analysis of 755 human serum samples (321 from PCR+ patients; 288 from PCR- patients; 115 from prepandemic individuals and classified as hospitalized, admitted to intensive-care unit (ICU), and exitus) from three independent cohorts has shown that the chips perform with a 98% specificity and 91% sensitivity identifying RT-PCR+ patients. Computational analysis utilized to correlate the immunological signatures of the samples analyzed indicate significant prediction rates against exitus conditions with 82% accuracy, ICU admissions with 80% accuracy, and 73% accuracy over hospitalization requirement compared to asymptomatic patients' fingerprints. The miniaturized microarray chip allows simultaneous determination of 96 samples (24 samples/slide) in 90 min and requires only 10 μL of sera. The diagnostic approach presented for the first time here could have a great value in assisting clinicians in decision-making based on the information provided by the Immuno-μSARS2 regarding progression of the disease and could be easily implemented in diagnostics of other infectious diseases.